JP2006519791A - 新規なｎｐｈインスリン製剤 - Google Patents

新規なｎｐｈインスリン製剤 Download PDF

Info

Publication number
JP2006519791A
JP2006519791A JP2006504321A JP2006504321A JP2006519791A JP 2006519791 A JP2006519791 A JP 2006519791A JP 2006504321 A JP2006504321 A JP 2006504321A JP 2006504321 A JP2006504321 A JP 2006504321A JP 2006519791 A JP2006519791 A JP 2006519791A
Authority
JP
Japan
Prior art keywords
alkyl
pharmaceutical formulation
aryl
optionally substituted
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006504321A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006519791A5 (de
Inventor
バルシュミット、パー
オルセン、ヘレ・ビルク
カールスホルム、ニエルス・シー．
マドセン、ペーター
ヤコブセン、パッレ
ルドビグセン、スベンド
シュルッケビエル、ゲルド
ステーンスガールド、ドルテ・ブジェルレ
ペーターセン、アンデルス・クラルスコブ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of JP2006519791A publication Critical patent/JP2006519791A/ja
Publication of JP2006519791A5 publication Critical patent/JP2006519791A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2006504321A 2003-03-13 2004-03-12 新規なｎｐｈインスリン製剤 Withdrawn JP2006519791A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200300383 2003-03-13
US45534103P 2003-03-17 2003-03-17
PCT/DK2004/000160 WO2004080481A1 (en) 2003-03-13 2004-03-12 Novel nph insulin preparations

Publications (2)

Publication Number Publication Date
JP2006519791A true JP2006519791A (ja) 2006-08-31
JP2006519791A5 JP2006519791A5 (de) 2007-04-19

Family

ID=32992157

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006504321A Withdrawn JP2006519791A (ja) 2003-03-13 2004-03-12 新規なｎｐｈインスリン製剤

Country Status (3)

Country Link
EP (1) EP1605967A1 (de)
JP (1) JP2006519791A (de)
WO (1) WO2004080481A1 (de)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016135778A (ja) * 2015-01-16 2016-07-28 大塚製薬株式会社 シアノトリアゾール化合物の医薬用途
JP2016525069A (ja) * 2013-07-17 2016-08-22 大塚製薬株式会社 シアノトリアゾール化合物
JP2019510787A (ja) * 2016-04-05 2019-04-18 イミューン センサー リミテッド ライアビリティ カンパニー ｃＧＡＳアンタゴニスト化合物

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2918286T (pt) * 2004-10-05 2020-03-27 Novo Nordisk As Formulação farmacêutica
WO2006104396A1 (en) * 2005-03-26 2006-10-05 Protemix Corporation Limited Pre-complexed copper antagonist compositions
WO2006104400A1 (en) * 2005-03-26 2006-10-05 Protemix Corporation Limited Copper antagonist compositions
JP2009500401A (ja) * 2005-07-07 2009-01-08 ポステック ファンデーション 糖吸収調節剤及び薬学的組成物
ES2431050T3 (es) 2005-08-04 2013-11-22 Sirtris Pharmaceuticals, Inc. Benzotiazoles y tiazolopiridinas como moduladores de la sirtuína
JP5191155B2 (ja) * 2006-03-27 2013-04-24 大塚製薬株式会社 カルボスチリル化合物からなる医薬
CL2008001821A1 (es) 2007-06-20 2009-03-13 Sirtris Pharmaceuticals Inc Compuestos derivados de imidazo[2,1-b]-tiazol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de diabetes, sindrome metabolico, resistencia a la insulina, entre otras.
CN102731429A (zh) * 2012-07-18 2012-10-17 西南大学 5-芳亚甲基噻唑烷-2，4-二酮及其合成方法和应用
MX2017007607A (es) 2014-12-11 2018-05-28 Harvard College Inhibidores de necrosis celular y metodos relacionados.
US11213513B2 (en) 2017-02-24 2022-01-04 The Regents Of The University Of California Compositions and methods for promoting hair growth with Mpc1 inhibitors
IL271443B2 (en) * 2017-06-30 2024-01-01 Univ California Preparations and methods for regulating hair growth
JP7231610B2 (ja) * 2017-07-28 2023-03-01 ノバルティス アーゲー インドール誘導体及びその使用
CN113929588B (zh) * 2020-06-29 2023-08-15 沈阳化工研究院有限公司 一种合成4-氨基甲基苯甲酸的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3060093A (en) * 1957-07-18 1962-10-23 Nordisk Insulinlab Slowly acting insulin preparation in crystalline form and method of preparation
US5830999A (en) * 1995-01-26 1998-11-03 Regents Of The University Of California Stabilization of insulin through ligand binding interations
WO1999021578A1 (en) * 1997-10-24 1999-05-06 Eli Lilly And Company Insoluble insulin compositions
US6531448B1 (en) * 1997-12-23 2003-03-11 Eli Lilly And Company Insoluble compositions for controlling blood glucose
EP1396272A1 (de) * 1997-12-23 2004-03-10 Eli Lilly & Company Unlöslische Insulin Zusammensetzungen zur Regelung der Blutglukose
JP2002529514A (ja) * 1998-11-18 2002-09-10 ノボ ノルディスク アクティーゼルスカブ フェノール及びクレゾールを要さない安定なインスリン水性調製物
WO2003053460A1 (en) * 2001-12-19 2003-07-03 Eli Lilly And Company Crystalline compositions for controlling blood glucose

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016525069A (ja) * 2013-07-17 2016-08-22 大塚製薬株式会社 シアノトリアゾール化合物
US10626095B2 (en) 2013-07-17 2020-04-21 Otsuka Pharmaceutical Co., Ltd. Cyanotriazole compounds
JP2016135778A (ja) * 2015-01-16 2016-07-28 大塚製薬株式会社 シアノトリアゾール化合物の医薬用途
JP2019510787A (ja) * 2016-04-05 2019-04-18 イミューン センサー リミテッド ライアビリティ カンパニー ｃＧＡＳアンタゴニスト化合物
JP7116422B2 (ja) 2016-04-05 2022-08-10 イミューン センサー リミテッド ライアビリティ カンパニー ｃＧＡＳアンタゴニスト化合物
US11597707B2 (en) 2016-04-05 2023-03-07 Immunesensor Therapeutics, Inc. CGAS antagonist compounds

Also Published As

Publication number Publication date
EP1605967A1 (de) 2005-12-21
WO2004080481A1 (en) 2004-09-23

Similar Documents

Publication Publication Date Title
JP2007523842A (ja) 酸安定化されたインスリンを含有する薬学的製剤
US7879893B2 (en) Ligands for the HisB10 Zn2 + sites of the R-state insulin hexamer
US20090123563A1 (en) Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand
JP2008505866A (ja) インスリンを含有する薬学的製剤
JP2006519791A (ja) 新規なｎｐｈインスリン製剤
Langoth et al. Thiolated chitosans: design and in vivo evaluation of a mucoadhesive buccal peptide drug delivery system
ES2297227T3 (es) Composiciones farmaceuticas conteniendo insulina y ligandos del hexamero de insulina.
US20060069013A1 (en) Pharmaceutical preparations comprising acid-stabilised insulin
JP2010504281A (ja) アリールスルファニル化合物、および活性薬剤を送達するための組成物
MXPA06013251A (es) Compuestos y composiciones de aril-cetona para suministrar agentes activos.
US20050065066A1 (en) Stabilised insulin compositions
US20060258561A1 (en) Novel NPH insulin preparations
JP2006519791A5 (de)
AU2002340773A1 (en) Novel ligands for the HisB10 Zn2+ sites of the R-state insulin hexamer
ZA200401839B (en) Novel ligands for the HisB10 Zn2+ sites of the R-state insulin hexamer.
KR20040044932A (ko) Ｒ－상태 인슐린 헥사머의 ＨｉｓＢ10 Ｚｎ2＋ 부위에대한 신규한 리간드
JPS5846026A (ja) ヒトインシユリン，ヒトｃ−ペプタイドおよびヒトプロインシユリン含有製剤
CN116635023A (zh) 用于治疗糖尿病的离子液体制剂
JP2002500187A (ja) 多発性硬化症の治療方法
JP2023539699A (ja) 糖尿病を治療するためのイオン性液体製剤
JPWO2020234782A5 (de)
WO2002072099A1 (fr) Agent therapeutique et / ou prophylactique pour la cardiopathie ischemique diabetique
JPS63132884A (ja) 新規のチオナフテン−２−カルボン酸の水溶性塩

Legal Events

Date Code Title Description
A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070302

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070302

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20080630